Piperidine quaternary salts- CCR- 3 receptor antagonists

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S316000, C514S318000, C514S321000, C514S324000, C514S326000, C514S330000, C546S233000, C546S234000, C546S235000, C546S237000

Reexamination Certificate

active

06342509

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to certain piperidine quaternary salts that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
BACKGROUND INFORMATION
Tissue eosinophilia is a feature of a number of pathological conditions such as asthma, rhinitis, eczema and parasitic infections ((see Bousquet, J. et al.
N. Eng. J. Med
. 323: 1033-1039 (1990) and Kay, A. B. and Corrigan. C. J.
Br. Med. Bull
. 48:51-64 (1992)). In asthma, eosinophil accumulation and activation are associated with damage to bronchial epithelium and hyperresponsiveness to constrictor mediators. Chemokines such as RANTES, eotaxin and MCP-3 are known to activate eosinophils ((see Baggiolini, M. and Dahinden, C. A.
Immunol. Today
. 15:127-133 (1994), Rot, A. M. et al.
J. Exp. Med
. 176, 1489-1495 (1992) and Ponath. P. D. et al.
J. Clin. Invest
., Vol. 97, #3, 604-612 (1996)). However, unlike RANTES and MCP-3 which also induce the migration of other leukocyte cell types, eotaxin is selectively chemotactic for eosinophils ((see Griffith-Johnson, D. A et al.
Biochem. Biophy. Res. Commun
. 197:1167 (1993) and Jose, P. J. et al.
Biochem. Biophy. Res. Commun
. 207, 788 (1994)). Specific eosinophil accumulation was observed at the site of administration of eotaxin whether by intradennal or intraperitoneal injection or aerosol inhalation ((see Griffith-Johnson, D. A et al.
Biochem. Biophy. Res. Commun
. 197:1167 (1993); Jose, P. J. et al.
J. Exp. Med
. 179, 881-887 (1994); Rothenberg, M. E. et al.
J. Exp. Med
. 181, 1211 (1995) and Ponath. P. D.
J. Clin. Invest
., Vol. 97, #3, 604-612 (1996)).
Glucocorticoids such as dexamethasone, methprednisolone and hydrocortisone have been used for treating many eosinophil-related disorders, including bronchial asthma ((R. P. Schleimer et. al.,
Am. Rev. Respir. Dis
., 141, 559 (1990)). The glucocorticoids are believed to inhibit IL-5, IL3 mediated eosinophil survival in these diseases. However, prolonged use of glucocorticoids can lead to side effects such as glaucoma, osteoporosis and growth retardation in the patients ((see Hanania N. A et al.,
J. Allergy and Clin. Immunol
., Vol. 96, 571-579 (1995) and Saha M. T. et al,
Acta Paediatrica
, Vol. 86, #2, 138-142 (1997)). It is therefore desirable to have an alternative means of treating eosinophil related diseases without incurring these undesirable side effects.
Recently, the CCR-3 receptor was identified as a major chemokine receptor that eosinophils use for their response to eotaxin, RANTES and MCP-3. When transfected into a murine pre-&bgr; lymphoma line, CCR-3 bound eotaxin, RANTES and MCP-3 and conferred chemotactic responses on these cells to eotaxin, RANTES and MCP-3 ((see Ponath. P. D. et al.
J. Exp. Med
. 183, 2437-2448 (1996)). The CCR-3 receptor is expressed on the surface of eosinophils, T-cells (subtype Th-2), basophils and mast cells and is highly selective for eotaxin.
Studies have shown that pretreatment of eosinophils with an anti-CCR-3 mAb completely inhibits eosinophil chemotaxis to eotaxin, RANTES and MCP-3 ((see Heath H. et al.
J. Clin. Invest
., Vol. 99, #2, 178-184 (1997)). Applicants' U.S. patent application Ser. No. 09/134,013, filed Aug. 14, 1998 discloses compounds that are CCR-3 antagonists and inhibit eosinophilic recruitment by chemokines such as eotaxin. PCT Application WO 98/04554 discloses piperidine analogs that are CCR-3 receptor antagonists.
Therefore, blocking the ability of the CCR-3 receptor to bind RANTES, MCP-3 and eotaxin and thereby preventing the recruitment of eosinophils should provide for the treatment of eosinophil-mediated inflammatory diseases.
The present invention concerns novel piperidine quaternary salts which are capable of inhibiting the binding of eotaxin to the CCR-3 receptor and thereby provide a means of combating eosinophil induced diseases, such as asthma.
SUMMARY OF THE INVENTION
In a first aspect, this invention provides compounds selected from the group of compounds represented by Formula (I):
wherein:
One of T and U is —N
+
R
5
— where R
5
is alkyl, haloalkyl, cyanoalkyl, hydroxyalkyl, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, amidoalkyl, sulfonylaminoalkyl, or aralkyl and the other is —CH—;
X

is a pharmaceutically acceptable counterion;
R
1
and R
2
are, independently of each other, hydrogen or alkyl;
m is an integer from 0 to 3 provided that when T is —N
+
R
5
— then m is at least 1;
Ar and Ar
1
are, independently of each other, aryl or heteroaryl;
F is alkylene, alkenylene, or a bond;
R is hydrogen or alkyl; or R together with either R
3
or R
4
and the atoms to which they are attached forms a carbocycle or a heterocycle;
R
3
and R
4
are, independently of each other, hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, heteroalkyl, or -(alkylene)-C(O)—Z where Z is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, mono- or disubstituted amino, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy;
E is —C(O)N(R
6
)—, —SO
2
N(R
6
)—, —N(R
7
)C(O)N(R
6
)—, —N(R
7
)SO
2
N(R
6
)—, —N(R
7
)C(S)N(R
6
)—, —N(R
7
)C(O)— or —N(R
7
)SO
2
— where:
R
6
and R
7
are, independently of each other, hydrogen, alkyl, acyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heteroalkyl, or -(alkylene)-C(O)—Z where Z is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, mono- or disubstituted amino, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy;
Q is —CO— or an alkylene chain optionally interrupted by —C(O)—, —NR
8
—, —O—, —S(O)
0−2
—, —C(O)N(R
8
)—, —N(R
8
)C(O)—, —N(R
8
)SO
2
—, —SO
2
N(R
8
)—, —N(R
9
)C(O)N(R
10
)—, —N(R
9
)SO
2
N(R
10
)— or —N(R
9
)C(S)N(R
10
)— where:
R
8
, R
9
and R
10
are, independently of each other, hydrogen, alkyl, acyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heterocyclylalkyl, heteroalkyl, or -(alkylene)-C(O)—Z where Z is alkyl, haloalkyl, alkoxy, haloalkyloxy, hydroxy, amino, mono- or disubstituted amino, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, or heteroaralkyloxy; and
prodrugs, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof.
In a second aspect, this invention provides pharmaceutical compositions containing a therapeutically effective amount of a compound of Formula (I) or its pharmaceutically acceptable salt and a pharmaceutically acceptable excipient.
In a third aspect, this invention provides a method of treatment of a disease in a mammal treatable by administration of a CCR-3 receptor antagonist, comprising administration of a therapeutically effective amount of a compound of Formula (I) or its pharmaceutically acceptable salt. The disease states include respiratory diseases such as asthma.
In a fourth aspect, this invention provide a process for preparing compounds of Formula (I).
DETAILED DESCRIPTION OF THE INVENTION
Definitions
Unless otherwise stated, the following terms used in the specification and claims have the meanings given below:
“Alkyl” means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., methyl, ethyl, propyl, 2-propyl, pentyl, and the like.
“Alkenyl” means a linear monovalent hydrocarbon radical of two to six carbon atoms or a branched monovalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, e.g., ethenyl, propenyl, and the like.
“Alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, e.g., methylene, ethylene, propylene, 2-methylpropylene, pentylene, and the like.
“Alkenylene” means a linear divalent hydrocarbon radical of two to six carbon atoms or

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Piperidine quaternary salts- CCR- 3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Piperidine quaternary salts- CCR- 3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidine quaternary salts- CCR- 3 receptor antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2819445

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.